Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multicenter, Randomized, Controlled, Multi-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD

NCT04744662 is registered in ClinicalTrials.gov with ONL Therapeutics as lead sponsor.

NCT NCT04744662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04744662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multicenter, Randomized, Controlled, Multi-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD
Lead sponsor
ONL Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2021
Completion date
February 29, 2024
Enrollment
28 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy